. Wycislo KL, Fan TM. The immunotherapy of canine osteosarcoma: a historical and systematic review. J VET INTERN MED 2015, 29(3):759-769.
. Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment - where do we stand? A state of the art review. CANCER TREAT REV 2014, 40(4):523-532.
. Zhao J, Dean DC, Hornicek FJ, et al. Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy. CANCER LETT 2020, 474:158-167.
. Tsuda Y, Tsoi K, Parry MC, et al. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma. BONE JOINT J 2020, 102-B(6):795-803.
. Sarkies P, Miska EA. Small RNAs break out: the molecular cell biology of mobile small RNAs. Nat Rev Mol Cell Biol 2014, 15(8):525-535.
. Lai WF, Lin M, Wong WT. Tackling Aging by Using miRNA as a Target and a Tool. TRENDS MOL MED 2019, 25(8):673-684.
. Jin W, Han H, Liu D. Downregulation miR-539 is associated with poor prognosis of gastric cancer patients and aggressive progression of gastric cancer cells. CANCER BIOMARK 2019, 26(2):183-191.
. Musilova K, Mraz M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. LEUKEMIA 2015, 29(5):1004-1017.
. Wen D, Li S, Jiang W, et al. miR-539 inhibits human colorectal cancer progression by targeting RUNX2. BIOMED PHARMACOTHER 2017, 95:1314-1320.
. Hu H, Zhang Y, Cai XH, et al. Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts. ONCOL LETT 2012, 4(5):1037-1042.
. Liu Y, Hong W, Zhou C, et al. miR-539 inhibits FSCN1 expression and suppresses hepatocellular carcinoma migration and invasion. ONCOL REP 2017, 37(5):2593-2602.
. Su H, Wang X, Song J, et al. MicroRNA-539 inhibits the progression of Wilms' Tumor through downregulation of JAG1 and Notch1/3. CANCER BIOMARK 2019, 24(1):125-133.
.Fook-Alves VL, de Oliveira MB, Zanatta DB, et al. TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) stable silencing increases late apoptosis by upregulation of caspase 9 and APAF1 in RPMI8226 multiple myeloma cell line. Biochim Biophys Acta 2016, 1862(6):1105-1110.
. Li Y, Tang X, He Q, et al. Overexpression of Mitochondria Mediator Gene TRIAP1 by miR-320b Loss Is Associated with Progression in Nasopharyngeal Carcinoma. PLOS GENET 2016, 12(7):e1006183.
. Liu P, Qi X, Bian C, et al. MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK. ONCOL LETT 2017, 13(6):4039-4046.
. Potting C, Tatsuta T, Konig T, et al. TRIAP1/PRELI complexes prevent apoptosis by mediating intramitochondrial transport of phosphatidic acid. CELL METAB 2013, 18(2):287-295.
. Yu T, Tong L, Ao Y, et al. Upregulation of TRIAP1 by the lncRNA MFI2-AS1/miR-125a-5p Axis Promotes Thyroid Cancer Tumorigenesis. Onco Targets Ther 2020, 13:6967-6974.
. Zhang J, Cong R, Zhao K, et al. High TRIAP1 expression in penile carcinoma is associated with high risk of recurrence and poor survival. Ann Transl Med 2019, 7(14):330.
.Hao CC, Luo JN, Xu CY, et al. TRIAP1 knockdown sensitizes non-small cell lung cancer to ionizing radiation by disrupting redox homeostasis. THORAC CANCER 2020, 11(4):1015-1025.
. Yu L, Meng M, Bao Y, et al. miR-1301/TRIAP1 Axis Participates in Epirubicin-Mediated Anti-Proliferation and Pro-Apoptosis in Osteosarcoma. YONSEI MED J 2019, 60(9):832-841.
. Rupaimoole R, Wu SY, Pradeep S, et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. NAT COMMUN 2014, 5:5202.
. Chen X, Xie D, Zhao Q, et al. MicroRNAs and complex diseases: from experimental results to computational models. BRIEF BIOINFORM 2019, 20(2):515-539.
. Hu Y, Dingerdissen H, Gupta S, et al. Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis. COMPUT BIOL MED 2018, 103:183-197..
. Lin Z, Li JW, Wang Y, et al. Abnormal miRNA-30e Expression is Associated with Breast Cancer Progression. CLIN LAB 2016, 62(1-2):121-128.
.Cui X, Zhang A, Liu J, et al. Down-regulation of MAP2K1 by miR-539 inhibits hepatocarcinoma progression. Biochem Biophys Res Commun 2018, 504(4):784-791.
.Deng H, Qianqian G, Ting J, et al. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1. BIOMED PHARMACOTHER 2018, 106:1072-1081.
.Ding S, Zhang Y. MicroRNA539 inhibits the proliferation and migration of gastric cancer cells by targeting SRYbox 5 gene. MOL MED REP 2019, 20(3):2533-2540.
. Gu L, Sun W. MiR-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1. Biochem Biophys Res Commun 2015, 464(4):1128-1133.
. Guo J, Gong G, Zhang B. miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer. Sci Rep 2018, 8(1):2073.
.Quan J, Qu J, Zhou L. MicroRNA-539 inhibits glioma cell proliferation and invasion by targeting DIXDC1. BIOMED PHARMACOTHER 2017, 93:746-753.
.Park WR, Nakamura Y. p53CSV, a novel p53-inducible gene involved in the p53-dependent cell-survival pathway. CANCER RES 2005, 65(4):1197-1206.
. Cai F, Chen L, Sun Y, et al. MiR-539 inhibits the malignant behavior of breast cancer cells by targeting SP1. BIOCHEM CELL BIOL 2020, 98(3):426-433.
. Yu H, Gao G, Cai J, et al. MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1. EXP MOL PATHOL 2019, 108:143-149.